<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01623908</url>
  </required_header>
  <id_info>
    <org_study_id>20110618GD</org_study_id>
    <nct_id>NCT01623908</nct_id>
  </id_info>
  <brief_title>Bone Loss Treatment From Adjuvant Zoledronate Efficacy</brief_title>
  <acronym>BLAZE</acronym>
  <official_title>An Open,Multicentre,Prospective Study of Adjuvant Zoledronate Treatment in Osteoporosis Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to observe and assess the impact of adjuvant zoledronate on&#xD;
      bone density in breast cancer patients.&#xD;
&#xD;
      The second purposes:&#xD;
&#xD;
        -  The efficacy of adjuvant zoledronate&#xD;
&#xD;
        -  The safety of adjuvant zoledronate&#xD;
&#xD;
        -  The bone loss of breast cancer patients in Guangdong&#xD;
&#xD;
        -  The correlation between bone loss of breast cancer patients and treatment of disease in&#xD;
           Guangdong&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the most commonly diagnosed malignant disease and the leading cause of&#xD;
      cancer-related mortality among women.&#xD;
&#xD;
      Zoledronate is a bone-targeted bisphosphonate, which is used to treat osteoporosis and to&#xD;
      reduce the risk of skeletal morbidity in patients with bone metastases. Zoledronate can also&#xD;
      reduce the persistence of disseminated tumour cells in the bone marrow of women with&#xD;
      early-stage breast cancer. Nowadays, consensus is emerging that certain subsets of patients&#xD;
      with early-stage breast cancer may benefit from bisphosphonate therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Bone Mineral Density</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone metastasis rate</measure>
    <time_frame>From date of randomization until the date of bone metastasis, assessed up to 48 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>From date of randomization until the date of bone metastasis or date of death from any cause, whichever came first, assessed up to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Bone Loss</condition>
  <arm_group>
    <arm_group_label>Zoledronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronate</intervention_name>
    <description>4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.</description>
    <arm_group_label>Zoledronate</arm_group_label>
    <other_name>Zometa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, age &gt; 18.&#xD;
&#xD;
          -  Postoperative breast cancer patients who have finished adjuvant chemotherapy or&#xD;
             unwilling to receive chemotherapy.&#xD;
&#xD;
          -  T score &lt; -2.0, or -2.0 &lt; T score &lt;-1.0 with any 2 of the following risk factors: T&#xD;
             score &lt; -1.5, age &gt; 65, BMI &lt; 20kg/m^2, family history of hip fractures, age &gt; 50 with&#xD;
             brittle fracture history, oral steroid therapy &gt; 6 months, receiving aromatase&#xD;
             therapy.&#xD;
&#xD;
          -  ECOG(Eastern Cooperative Oncology Group) physical state score:0-2.&#xD;
&#xD;
          -  Breast cancer stage I-III confirmed by histological or cytological examination.&#xD;
&#xD;
          -  Patients received radical surgery with estimated survival time &gt; 12 months.&#xD;
&#xD;
          -  Laboratory tests should be performed 1 week before enrollment and the results should&#xD;
             meet the following criteria: neutrophil count ≥ 1.5×10^9/L, platelet count ≥&#xD;
             100×10^9/L, hemoglobin ≥ 80g/L, serum bilirubin ≤ 1.0×ULN, AST and ALT ≤ 1.5×ULN,&#xD;
             Serum creatinine ≤ 1.0×ULN.&#xD;
&#xD;
          -  Patients who never received intravenous bisphosphonate within 12 months before&#xD;
             enrollment and did not receive oral bisphosphonate within 3 weeks before enrollment.&#xD;
&#xD;
          -  Informed consents should be signed by the participants or their guardians. All the&#xD;
             participants should be aware of the purpose and procedure of this study and willing to&#xD;
             participate in this study.&#xD;
&#xD;
          -  Contraception required for those reproductive-aged women.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients who have not signed informed consent.&#xD;
&#xD;
          -  Patients received medical treatment which can affect bone metabolism (such as&#xD;
             calcitonin, mithramycin or gallium nitrate) within 2 weeks before enrollment.&#xD;
&#xD;
          -  Bone metabolic diseases such as Paget's disease, epiphyseal dysplasia and primary or&#xD;
             secondary hyperthyroidism diagnosed within 12 months before enrollment.&#xD;
&#xD;
          -  Liver function impairment which is defined as 2.5-fold or more increase in ALT or AST&#xD;
             levels compared with the upper limit of reference range.&#xD;
&#xD;
          -  Refuse appropriate contraception (appropriate contraceptive options include female&#xD;
             sterilisation, intrauterine device, oral contraceptives and barrier contraception).&#xD;
&#xD;
          -  Active dental diseases including dental infection, mandibular pain and maxillary or&#xD;
             mandibular trauma. Patients with mandibular osteonecrosis diagnosed currently or&#xD;
             previously, exposed bone or slow healing after oral surgery. Patients who will receive&#xD;
             dental or maxillofacial surgery (such as dental extraction and dental implant) in the&#xD;
             first 6 weeks after enrollment.&#xD;
&#xD;
          -  Patients with dysgnosia or communication disorder who can't well understand our study,&#xD;
             cooperate with our staff or operate glucose monitor correctly.&#xD;
&#xD;
          -  Combined with major organ dysfunction or other severe diseases such as severe coronary&#xD;
             disease, cardiovascular disease, myocardial infarction occurred within 12 months&#xD;
             before enrollment, severe neurological or psychiatric diseases, severe infection or&#xD;
             active disseminated intravascular coagulation.&#xD;
&#xD;
          -  Alcoholics or drug addicts.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenming Wang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ying Lin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dongguan People's Hospital</name>
      <address>
        <city>Dongguan</city>
        <state>Guangdong</state>
        <zip>523059</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Guangzhou Military Command of PLA</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GuangDong Hospital Of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou First Municipal People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen Second Municipal People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 16, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2012</study_first_posted>
  <last_update_submitted>June 19, 2021</last_update_submitted>
  <last_update_submitted_qc>June 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Ying Lin</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Breast neoplasms</keyword>
  <keyword>Zoledronate</keyword>
  <keyword>Bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

